Last updated: March 3, 2026
Case Overview
Vanda Pharmaceuticals Inc. filed a patent infringement suit against Apotex Inc. in the District of Columbia District Court. The case number is 1:21-cv-00282, filed on February 8, 2021. The dispute centers on patent rights related to Vanda’s formulation of a melatonin receptor agonist for treating sleep disorders.
Patent Details
Vanda asserted U.S. Patent No. 8,618,139, which covers a specific controlled-release formulation of tasimelteon. The patent claims a method for improving sleep by administering a controlled-release formulation of tasimelteon at a specified time. The patent was granted June 30, 2014, and extended through 2031.
Allegations
Vanda alleges that Apotex's proposed generic drug infringes its '139 patent by manufacturing, using, selling, or offering for sale a controlled-release formulation of tasimelteon that falls within the scope of the patent claims. The complaint emphasizes that Apotex's product aims to treat sleep disorders by mimicking Vanda's patented formulation.
Legal Proceedings
Patent Validity and Infringement
Vanda claims the patent is valid and enforceable, and that Apotex's generic infringing product directly violates the patent claims. Vanda seeks injunctive relief, damages for patent infringement, and a declaratory judgment that Apotex's product infringes the patent.
Invalidity Defenses and Challenges
Apotex counterclaims seeking to invalidate the '139 patent on multiple grounds, including obviousness under 35 U.S.C. § 103, anticipation under 35 U.S.C. § 102, and lack of patentable subject matter. Apotex asserts that the patent claims are obvious in light of prior art references, alleging that the controlled-release formulation is an obvious modification of existing compounds.
Recent Procedural Status
The case proceeded through initial disclosures, claim construction hearings, and motion practice. As of the latest update (mid-2023), both parties filed summary judgment motions. The court has scheduled a Markman hearing on claim construction for July 2023.
Key Patent Litigation Issues
Patent Validity
The main point of contention is whether the '139 patent's claims are obvious. The prior art includes earlier formulations of melatonin receptor agonists and controlled-release technologies. Apotex argues that combining these references would have been obvious to a person skilled in formulation science.
Infringement
Vanda argues Apotex's formulation is within the scope of the patent claims, asserting that the pharmacokinetic profile and controlled-release mechanism match the patented formulation. The specific challenge is whether the claims are broad enough to cover Apotex's product.
Patent Term and Extension
The patent's expiration is scheduled for 2031, providing Vanda with over eight years of exclusivity post-litigation, assuming patent validity is upheld and no invalidity defenses succeed.
Litigation Outcomes and Implications
As of the current status, the case remains active. A ruling on the validity of the patent and the infringement determination will significantly affect Apotex's ability to launch a generic version of tasimelteon for sleep disorders.
Anticipated Impacts
- If the patent survives invalidity challenges, exclusivity until 2031 remains.
- An invalidation would open the market for generic competition, estimated at $200 million annual sales.
- The case exemplifies ongoing patent disputes over formulation patents in sleep disorder therapies and molecular-specific drugs.
Comparative Context
This case follows a pattern seen in pharmaceutical patent litigations, where patent holders defend formulation patents against generic challengers using obviousness and anticipation defenses. Similar cases include Apotex v. Lundbeck (2010) and Teva v. GSK (2014), where validity and infringement issues centered on formulation and method-of-use patents.
Key Takeaways
- The lawsuit hinges on patent validity, specifically obviousness arguments.
- The patent covers a specific controlled-release formulation of tasimelteon.
- The case's resolution will influence both market exclusivity and generic entry for sleep disorder treatments.
- A court ruling on claim construction scheduled for mid-2023 will guide subsequent proceedings.
- Patent rights are under challenge from multiple angles, reflecting common pharmaceutical patent litigation risks.
FAQs
1. What are the grounds for Apotex's invalidity claims?
Apotex argues the patent is invalid due to obviousness, anticipation by prior art, and lack of inventive step, citing earlier formulations and controlled-release technologies.
2. How does the patent's expiration date affect the case?
The patent expires in 2031. A finding of validity confirms Vanda’s market exclusivity until then, barring generic competition. Invalidity would allow generic entry, impacting market share.
3. What is the significance of the Markman hearing?
The hearing on claim construction clarifies the scope of patent claims, which directly impacts infringement and validity disputes.
4. Are there any comparable cases?
Yes, cases such as Apotex v. Lundbeck (2010) and Teva v. GSK (2014) involved similar formulation and patent validity issues, influencing outcomes of patent challenges.
5. What could be the potential damages if infringement is proven?
Damages could include lost profits, reasonable royalties, and injunctive relief. A successful infringement claim can also delay generic market entry, extending exclusivity.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,618,139.
- Court filings in Vanda Pharmaceuticals Inc. v. Apotex Inc., 1:21-cv-00282 (D.D.C., 2021).
- Federal Circuit decisions on pharmaceutical patent validity and infringement.
